Agile Partnerships Drive Faster Pharma Innovation on April 21, 2026 agile biopharma CDMO Drug Development partnerships pharma innovation +
Galux Raises $29M Series B for AI Protein Design on February 10, 2026 AI protein design Funding Galux MEMO1 gene methionine partnerships Series B SMPX gene +
Eli Lilly Strikes Multiple Deals for Ultra-Rare Eye Disease Gene Therapy and RNAi Partnerships on November 10, 2025 AAV-AIPL4 eli lilly gene therapy Genetic Leap Leber congenital amaurosis-4 MeiraGTx Ophthalmology specialty partnerships RNA Interference SanegeneBio +
Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact on October 28, 2025 Clearmind Medicine Clinical Trials governmental engagement Mary-Elizabeth mental health partnerships psychedelic medicine regulatory advocacy U.S. +
Meeting on the Mesa 2025 Arrives Amid Mixed Signals for Cell and Gene Therapy Sector on October 06, 2025 advanced therapies Alternative Cells Clinical Trials commercialization Gene Modification gene therapy Industry meeting MESA partnerships payment Phoenix Arizona regulatory challenges RNA, Messenger Study models +
Lundbeck Offloads Assets to Three Partners as It Exits 27 Markets, Leaving 602 Jobless on September 10, 2025 asset Exit Lundbeck Market neuro-rare diseases neuro-specialty diseases NewBridge Pharmaceuticals offloading partnerships restructuring Swixx Group Zuellig Pharma +
AstraZeneca's China woes recede as focus shifts to upcoming readouts on April 30, 2025 Acquisition Beijing biotech China China legal issues resolution FibroGen Fine - adjective global strategic R&D center Investments manufacturing partnerships R&D +
Tempest Seeks Strategic Partners to Launch Phase 3 Liver Cancer Trial Amid Funding Challenges on April 10, 2025 altretamine/cisplatin/cyclophosphamide protocol amezalpat biotech Liver and Intrahepatic Biliary Tract Carcinoma partnerships Peroxisome Proliferator-Activated Receptors Phase 3 Trial strategic +